FAQs
What is the average soliris price per year in the United States?
The pre‑discount soliris price per year typically ranges from $650,000 to $764,000, depending on the dosing schedule, infusion fees, and regional pricing variations.
Why is soliris so expensive compared with other medicines?
Soliris is a recombinant monoclonal antibody that requires complex manufacturing, serves a very small patient population, and benefits from orphan‑drug exclusivity, all of which drive the high per‑patient cost.
Are there discounts or assistance programs that can lower the cost?
Yes. Patients can often access manufacturer copay‑card programs, income‑based patient‑assistance grants, and negotiated insurer discounts (e.g., ICER‑mandated reductions) that can reduce out‑of‑pocket expenses dramatically.
How does insurance coverage affect the overall cost of soliris?
Insurance can apply formulary tiers, negotiate bulk discounts, and combine with copay‑card benefits. While the list price remains high, many insurers cover a large portion after these negotiations, lowering the patient’s share.
Are there alternative treatments that are less costly?
Ultomiris (ravulizumab) offers a similar mechanism with a once‑monthly dosing schedule and generally costs between $500,000 and $600,000 per year, still high but slightly lower than Soliris.
